AMENDED AND RESTATED LICENSE AGREEMENT FOR PDKLicense Agreement • March 10th, 2020 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED LICENSE AGREEMENT FOR PDK (the “Agreement”), effective as of December 13, 2019 (the “Separation Effective Date”), is made by and between Sunesis Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 395 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080 (“Sunesis”), and Millennium Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 40 Landsdowne Street, Cambridge, Massachusetts 02139 (“Millennium”). Sunesis and Millennium are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
